


Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests: A Workshop October 28-29, 2024



National Cancer Policy Forum

[Workshop Website](#)

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

WORKSHOP AGENDA

MONDAY, OCTOBER 28, 2024 8:30 am to 5:00 pm ET	
8:00 am	Breakfast and Registration (30 minutes)
8:30 am	Welcome and Introductory Remarks (30 minutes) <i>Planning Committee Co-chairs:</i> Beth Karlan, University of California, Los Angeles Lawrence Shulman, University of Pennsylvania
9:00 am	Session 1: Overview of Multicancer Detection Testing (1 hour, 45 minutes) <i>Co-Moderators:</i> Beth Karlan, University of California, Los Angeles Lawrence Shulman, University of Pennsylvania <i>Session Objectives</i> <ul style="list-style-type: none"> Highlight the rationale, challenges, and opportunities for MCD testing to improve outcomes for patients with cancer. Keynote Presentation: How Much Do You Want to Know? The Peril and Promise of an MCD-Driven Future (20 minutes) <ul style="list-style-type: none"> W. Kimryn Rathmell, National Cancer Institute History of Cancer Early Detection Studies (15 minutes) <ul style="list-style-type: none"> Robert Smith, American Cancer Society How Multicancer Detection Testing Works (15 minutes) <ul style="list-style-type: none"> William Grady, Fred Hutchinson Cancer Center Panel Discussion (55 minutes) Include Speakers and: <ul style="list-style-type: none"> Cheryl Ivey Green, First Baptist Church of South Richmond Jody Hoyos, Prevent Cancer Foundation Sue Friedman, Facing Our Risk of Cancer Empowered (<i>participating virtually</i>) Christos Patriotis, National Cancer Institute

10:45 am	Break (15 minutes)
11:00 am	<p>Session 2: MCD Test Validation (1 hour, 30 minutes) <i>Co-Moderators:</i> Ruth Etzioni, Fred Hutchinson Cancer Center Beth Karlan, University of California, Los Angeles</p> <p><i>Session Objectives</i></p> <ul style="list-style-type: none"> To examine analytical validation, clinical validation, and clinical utility of MCD tests, as well as challenges of and strategies for assessing the clinical utility and effectiveness of MCD tests (e.g., improved patient outcomes; reduced cancer mortality). Discuss research gaps and opportunities to build the evidence base. <p>Diagnostic Performance: The Many Faces of Screening Test Sensitivity (10 minutes)</p> <ul style="list-style-type: none"> Ruth Etzioni, Fred Hutchinson Cancer Center <p>Clinical Trials for Evaluating the Mortality Benefits of MCD Testing (10 minutes)</p> <ul style="list-style-type: none"> Hormuzd Katki, National Cancer Institute <p>Alternative Endpoints for MCD Clinical Trials (10 minutes)</p> <ul style="list-style-type: none"> Hilary Robbins, International Agency for Research on Cancer <i>(participating virtually)</i> <p>Addressing the Gap between Performance and Outcomes in the Absence of MCD Randomized Trials (10 minutes)</p> <ul style="list-style-type: none"> Jane Lange, Cancer Early Detection Advanced Research Center (CEDAR), Oregon Health and Science University <p>Panel Discussion (50 minutes) Include Speakers and:</p> <ul style="list-style-type: none"> Philip Castle, National Cancer Institute
12:30 pm	Lunch (1 hour)
1:30 pm	<p>Session 3: Examples of MCD Tests in Development and Clinical Use (1 hour, 20 minutes) <i>Co-Moderators:</i> Philip Castle, National Cancer Institute Lawrence Shulman, University of Pennsylvania</p> <p><i>Session Objectives</i></p> <ul style="list-style-type: none"> To explore the development and clinical use of MCD tests <p>Overview of MCD Tests in Development and Clinical Practice (15 minutes)</p> <ul style="list-style-type: none"> Wendy Rubinstein, National Cancer Institute <p>Discussion of Evidence: Industry Perspective (65 minutes) Include Speakers and:</p> <ul style="list-style-type: none"> Tomasz Beer, Exact Sciences Craig Eagle, Guardant Health Eric Klein, GRAIL

2:50 pm	Break (15 minutes)
3:05 pm	<p>Session 4: Strategies for Implementing MCD Tests into Clinical Practice (1 hour, 55 minutes) <i>Co-Moderators:</i> Elena Martínez, University of California, San Diego Chanita Hughes-Halbert, University of Southern California</p> <p><i>Session Objectives</i></p> <ul style="list-style-type: none"> To examine the impact of MCD tests on the landscape of cancer screening, detection, diagnosis, and treatment, as well as considerations for follow-up patient care. <p>Primary Care Perspective (10 minutes)</p> <ul style="list-style-type: none"> Richard Hoffman, University of Iowa <p>Radiology Perspective (10 minutes)</p> <ul style="list-style-type: none"> Stella Kang, New York University Langone Health <p>Oncology Care Perspective (10 minutes)</p> <ul style="list-style-type: none"> Deborah Schrag, Memorial Sloan Kettering Cancer Center <p>Health Care Delivery System Perspective (10 minutes)</p> <ul style="list-style-type: none"> Nancy Keating, Harvard Medical School and Brigham and Women’s Hospital <p>Implementation Sciences Perspective (10 minutes)</p> <ul style="list-style-type: none"> Ora Gordon, Saint John’s Cancer Institute and Providence Health <p>Guideline Development Perspective (10 minutes)</p> <ul style="list-style-type: none"> Alex Krist, Virginia Commonwealth University <p>Panel Discussion (55 minutes) Include Speakers and:</p> <ul style="list-style-type: none"> Ronald Myers, Thomas Jefferson University Chyke Doubeni, The Ohio State University
5:00 pm	Adjourn and Reception

TUESDAY, OCTOBER 29, 2024
8:30 am to 11:30 am ET

8:00 am	Breakfast and Registration (30 minutes)
8:30 am	<p>Session 5: Health System and Policy Considerations (1 hour, 30 minutes) <i>Co-Moderators:</i> Etta Pisano, American College of Radiology Robert Winn, Massey Comprehensive Cancer Center, Virginia Commonwealth University</p> <p><i>Session Objectives</i></p> <ul style="list-style-type: none"> To understand policy considerations related to MCD tests' impact on cancer care, patient outcomes, and health equity. <p>Health Equity Considerations with MCD Testing (20 minutes)</p> <ul style="list-style-type: none"> Carmen Guerra, Penn Medicine, University of Pennsylvania Rachel Issaka, Fred Hutchinson Cancer Center <p>Health Economic Considerations (20 minutes)</p> <ul style="list-style-type: none"> Ya-Chen Tina Shih, University of California, Los Angeles Scott Ramsey, Fred Hutchinson Cancer Center <p>Health Insurance and Coverage Considerations (20 minutes)</p> <ul style="list-style-type: none"> Jill Hagenkord, Optum Genomics Kathryn Phillips, University of California, San Francisco <p>Panel Discussion (30 minutes)</p>
10:00 am	Break (15 minutes)
10:15 am	<p>Session 6: Wrap Up Discussion (1 hour, 15 minutes) <i>Co-Moderators:</i> Beth Karlan, University of California, Los Angeles Lawrence Shulman, University of Pennsylvania</p> <p>Session 1: Beth Karlan and Lawrence Shulman Session 2: Ruth Etzioni and Justin Bekelman Session 3: Lawrence Shulman Session 4: Elena Martínez and Chanita Hughes-Halbert Session 5: Etta Pisano and Robert Winn</p>
11:30 am	Adjourn